tive finding may have been due to the wide limits of error that were obtained in the bioassay.
Al-Tetrahydrocannabinol (Al-THC) is generally acknowledged to be the main centrally active principle of cannabis, while cannabidiol (CBD), another major naturally occurring cannabinoid is much less active centrally (Mechoulam, Shani, Edery & Grunfeld, 1970; Pertwee, unpublished observation) . However, unlike Al-THC, CBD is a potent inhibitor of hepatic drug metabolism (Paton & Pertwee, 1972) and this raises the question of whether CBD can inhibit the metabolism of A'-THC in vivo thereby affecting the concentration in the central nervous system of A'-THC and its metabolites. Of particular interest would be an effect on the concentration of 7-hydroxy-Al-THC, a metabolite reported (Christensen, Freudenthal, Gidley, Rosenfeld, Boegli, Testino, Brine, Pitt & Wall, 1971) (Paton & Pertwee, 1972) . A control group of 6 mice received intraperitoneal injections of Tween 80 in NaCl solution. Thirty minutes after the injection of CBD or its vehicle, each mouse received an intravenous injection of 3H-A'-THC. T;he A'-THC was labelled in positions 1 and 2 of the pentyl side chain and when used had a specific activity of 584 mCi/mmole (4-13 x 106 dpm/,ug); its synthesis is described elsewhere (Gill & Jones, 1972a) . The Al-THC was dispersed in a mixture of Tween 80 and a 0-9 % NaCl solution, the dispersion containing by weight 5 parts of Tween to 1 part of THC. The dose and volume injected were respectively 1 mg/kg and 0-2 ml/25 g.
The pharmacological response to the 'H-A'-THC was evaluated 15 min after the injection of Al-THC by means of the ring test, a bioassay which provides a measure of the 'cataleptic' effect of A'-THC. In the bioassay a mouse is placed across a horizontal wire ring of 5 5 cm diameter for periods of up to 6 minutes. The percentage of this time during which the mouse remains completely still is recorded and is called the 'immobility index'. Immediately after completion of the ring test, the mice were killed by administration of carbon monoxide. The method employed for the determination of brain levels of Al-THC and its metabolites has been described in detail by Gill & Jones (1972b) . Individual whole brains were removed and then rinsed and homogenized in 0-1 M phosphate buffer (pH 7-4). An aliquot of each homogenate was digested with methanolic hyamine hydroxide and the total radioactivity was measured by liquid scintillation counting. The remainder of the homogenate was extracted with purified ethyl acetate. The dried extract was counted and, after concentration under a stream of nitrogen, was chromatographed on silica-impregnated paper. The distribution of radioactivity in the chromatogram was determined by division into strips followed by elution of each strip with scintillator solution directly in the counting vials.
Results. Radioactive spots were observed with the Rf values of authentic Al-THC and 7-hydroxy-A'-THC, the primary metabolite, and the activity was provisionally assigned to these two compounds. In The results are summarized in Fig. 1 . It was found that the levels of the radioactivity in the brain assigned to A'-THC and its 7-hydroxy metabolite were both significantly (P<0 005) elevated by pretreatment with CBD, being respectively about 14 and 2 0 times greater in the mice pre-treated with CBD than in the mice which had received instead a Tween-NaCl solution. In addition, CBD significantly (P<0 02) reduced the brain level of the unidentified polar metabolite. However, no change was detected (P>0 1) in the level of the non-extractable material. These changes in levels of radioactivity were not accompanied by a corresponding behavioural change: the mean immobility index (+S.E.M.) of the group of mice pretreated with CBD was 515 (±125) whereas the mean immobility index of the control group was 52 2 (±4 9). and (2) the second stage of this metabolic pathway is inhibited to a greater extent than the first. It is of interest that SKF 525A, a better known metabolic inhibitor than CBD, produces qualitatively similar effects in vivo to those described here (Gill & Jones, 1972b) . Experiments concerned with 3H-A'-THC alone (Gill & Jones, 1972b) have demonstrated the existence of a highly significant correlation between the immobility index and the levels in the mouse brain of radioactivity assigned to A'-THC and 7-hydroxy-A'-THC. The failure of CBD pretreatment to produce a detectable change in the immobility index is interesting in view of a current hypothesis that 7-hydroxy-/'-THC may be solely responsible for the behavioural changes that follow administration of A1-THC (Mechoulam, 1970; Christensen, et al., 1971) . Pretreatment with CBD produced a two-fold increase in the level of radioactivity assigned to 7-hydroxy-A1-THC but proportionally a smaller change in the combined brain levels of A1-THC and 7-hydroxy-Al-THC. This suggests that the metabolite is not solely responsible for the behavioural changes that follow administration of A1-THC and that A'-THC itself contributes at least partly towards the effect. However, the wide limits of error that were obtained with the ring test prevent any definite conclusion from being reached. Both CBD and A'-THC are natural constituents of cannabis and the metabolic interaction that occurs between the two cannabinoids may well influence the pharmacology of the crude material. Unequivocal evidence to support this possibility could only be provided however by an experiment in which CBD and A'-THC were administered to animals at the same time, by the same route and in the same proportion to one another as the proportion in which they are found in cannabis.
